Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Depreciation & Amortization (CF) of $600000.0 for Q2 2026, up 20.0% year-over-year from $500000.0 in Q2 2025, and little changed quarter-over-quarter from $600000.0 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $600000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 20.0% year-over-year to $600000.0; the TTM figure through Jun 2026 stood at $2.2 million (up 18.2% YoY), while the FY2025 annual figure was $2.0 million, up 20.53% from the prior year.
- Depreciation & Amortization (CF) held at $600000.0 in Q2 2026 per DYN's latest filing, from $600000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $600000.0 in Q1 2026 and bottomed at $383000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $456666.7 across 5 years, with a median of $418500.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 150.0% — and 2023, when it dropped 20.0%.
- Dyne Therapeutics' Depreciation & Amortization (CF) stood at $383000.0 in 2022, then advanced by 4.44% to $400000.0 in 2023, then advanced by 19.25% to $477000.0 in 2024, then advanced by 9.22% to $521000.0 in 2025, then advanced by 15.16% to $600000.0 in 2026.
- Business Quant data shows DYN's Depreciation & Amortization (CF) at $600000.0 in Q2 2026, $600000.0 in Q1 2026, and $521000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Dyne Therapeutics | 4.02 Bn | 4.02 Bn | - | 600,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 600,000.00 |
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | 521,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 477,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 412,000.00 |
| Dec 31, 2022 | 383,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 425,000.00 |
| Dec 31, 2021 | 353,000.00 |
| Sep 30, 2021 | 300,000.00 |